

## SCHWERPUNKT: LIPIDE

- **Familiäre Hypercholesterinämie: Diagnostik, Screening und Implementierung leitliniengerechter Therapie (S. 7–11)**

*G. Klose, N. Schmidt, W. März*

### Literatur:

1. Ray K, EAS 2019 Amsterdam, Präsentation zitiert nach <https://pace-cme.org/2019/05/29/failure-to-identify-fh-results-in-worse-survival-compared-with-people-with-an-fh-diagnosis/>
2. Brown MS & Goldstein JL, Familial hypercholesterolemia: A genetic defect in the low-density lipoprotein receptor. *N Engl J Med.* 1976; 294(25): 1386–90
3. Sinderman AD et al. The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. *J Am Coll Cardiol.* 2014; 63(19): 1935–47
4. Schmidt N et al., Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: targets and Essential Data for Commitment of Treatment (DETECT) study, *Atherosclerosis* 2017; 266: 24–30
5. Sjouke B et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype – phenotype relationship, and clinical outcome. *European Heart Journal* 2015; 36: 560–565
6. Kayikcioglu M et al. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry). *Atherosclerosis* 2018; 277: 341–346
7. Fahed AC et al. Homozygous familial hypercholesterolemia in Lebanon: a genotype/phenotype correlation. *Mol Genet Metab* 2011; 102(2): 181–8
8. Horton JD et al. PCSK9: a convertase that coordinates LDL catabolism. *J Lipid Res* 2009; 50 Suppl: 172–7
9. Cuchel M et al., Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society, *Eur Heart J* 2014; 35(32): 2146–57
10. Marks D et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. *Atherosclerosis* 2003; 168(1): 1–14
11. Béliard S et al. The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients. *J Clin Lipidol* 2016 ;10(5): 1129–1136
12. Alonso R et al. Lipoprotein(a) Levels in Familial Hypercholesterolemia An Important Predictor of Cardiovascular Disease Independent of the Type of LDL Receptor Mutation. *J Am Coll Cardiol* 2014; 63: 1982–9
13. <https://www.fhscore.eu/#/fhQuestionnaire>. Letzter Zugriff: 01.2020
14. Klose G et al. Familiäre Hypercholesterinämie, Entwicklungen in Diagnostik und Behandlung. *Dtsch Arztebl Int* 2014; 111: 523–9

15. Mach F et al., 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *European Heart Journal* 2019; 41(1): 111–188
16. Ludt, S., et al. "Hausärztliche Risikoberatung zur kardiovaskulären Prävention: S3-Leitlinie." [www.awmf.org/uploads/tx\\_szleitlinien/053-024l\\_Hausaerztliche\\_Risikoberat\\_kardiovask\\_Prae\\_vention\\_2017-11\\_1.pdf](http://www.awmf.org/uploads/tx_szleitlinien/053-024l_Hausaerztliche_Risikoberat_kardiovask_Prae_vention_2017-11_1.pdf) 2017. Letzter Zugriff: 01.2020
17. <https://www.synlab.de/human/fuer-aerzte/fachinformationen/medizin/hypercholesterinaemie>. Letzter Zugriff: 01.2020
18. Pérez de Isla L et al. Predicting Cardiovascular Events in Familial Hypercholesterolemia: The SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). *Circulation*. 2017 ;135(22): 2133–2144
19. Khera AV et al. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. *J Am Coll Cardiol* 2016;67(22): 2578–89
20. Umans-Eckenhausen MA et al. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. *Arch Intern Med*. 2003 Jan 13; 163(1): 65–8
21. Vallejo-Vaz AJ et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Atherosclerosis* 2018; 277: 234–255
22. Schmidt N et al. CaRe high - Cascade screening and registry for high cholesterol in Germany. *Atheroscler Suppl* 2017; 30: 72–76
23. <https://www.dach-praevention.eu/care-high-kaskadenscreening/>. Letzter Zugriff: 01.2020
24. Schmidt N et al. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. *Atherosclerosis* 2018; 277: 314–322
25. Moriarty PM et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. *Eur Heart J* 2016; 37(48): 3588–3595
26. Baum SJ et al. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. *J Clin Lipidol* 2019; 13(6): 901–909
27. Raal F et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. *Lancet* 2015; 385(9965): 331–40
28. Raal FJ et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015; 385(9965): 341–50
29. Kastelein JJ et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. *Eur Heart J* 2015; 36(43): 2996–3003
30. Raal FJ. Safety and Efficacy of Inclisiran in Patients With Heterozygous Familial Hypercholesterolemia - Results From the Phase 3 ORION-9 Trial, Präsentation American Heart Association (AHA) 2019 Scientific Sessions am 18.11.2019

31. Thompson GR et al. Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol. *European Heart Journal* 2017; 39(14): 1162–1168
32. Blom DJ et al. Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis. *Curr Atheroscler Rep* 2019; 21(12): 48

- **Aktuelle Rolle der PCSK9-Inhibitoren bei der Behandlung von Hypercholesterinämie-Patienten (S. 19–27)**

*U. Julius, S. Tselmin, U. Schatz, S. Fischer, S. R. Bornstein*

**Literatur:**

1. Julius U. Wirkungsweise und Effekte der PCSK9-Inhibitoren. *herzmedizin* 2016: 22-27
2. Cannon CP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med* 2015; 372: 2387–97
3. Banach M & Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? *Cardiovasc Res* 2019; 115: e26–e31
4. Wong ND & Shapiro MD. Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials. *Front Cardiovasc Med* 2019; 6
5. Schwartz GG et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *N Engl J Med* 2018; 379: 2097–107
6. Sabatine MS et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *N Engl J Med* 2017;376:1713–22
7. Murphy SA et al. Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. *JAMA Cardiol* 2019; 4: 613–19
8. Ray KK et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY-OUTCOMES randomised controlled trial. *Lancet Diabetes Endocrinol* 2019; 7: 618–28
9. Julius U et al. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. *Clin Res Cardiol Suppl* 2019; 14: 45–50
10. Hollstein T et al. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. *Vascul Pharmacol* 2019; 116: 8–15
11. Ruscica M et al. PCSK9 inhibition and inflammation: A narrative review. *Atherosclerosis* 2019; 288: 146–55
12. Bohula, EA et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. *Circulation* 2018; 138: 131–40
13. Reiner Z. The association between lipid-lowering drugs and circulating concentration of PCSK9. *Eur J Prev Cardiol* 2019; 26: 928–29
14. Cao YX et al. Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy. *J Transl Med* 2019; 17: 367

15. Jukema JW et al. Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY-OUTCOMES Trial. *J Am Coll Cardiol* 2019; 26034
16. Spitthover R et al. Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis. *J Clin Apher* 2019; 21695
17. Baum, SJ et al. Effect of evolocumab on lipoprotein apheresis requirement and lipid levels: Results of the randomized, controlled, open-label DE LAVAL study. *J Clin Lipidol* 2019; 13: 901–09
18. Schatz U et al. Heterozygote familiäre Hypercholesterinämie - Schon niedrige Statindosis potenziert PCSK9i-Effekt. *CardioVasc* 2018; 18: 22–23
19. Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2019; 41(1): 111–188
20. Moriarty PM et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. *Eur. Heart J* 2016; 37(48): 3588–3595

- **Lipoprotein(a) in der kardiovaskulären Prävention – Ein Update (S. 28–32)**

*H. W. Hahmann*

**Literatur:**

1. Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *EurHeart J* 2019; 37(3): 2999
2. Tsimikas S et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease *NEJM* January 1, 2020: 1905239. DOI: 10.1056/NEJMoa1905239
3. Nordestgaard M et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *European heart journal* 2010; 31(23): 2844–2853
4. Krempler F et al. Turnover of lipoprotein(a) in man. *J Clin Invest* 1980; 65: 1483–1490
5. Utermann G et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. *J Clin Invest* 1987; 80: 458–465
6. Clarke R et al. Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. *N Engl J Med* 2009; 361: 2518–28
7. Hahmann HW et al. The significance of high levels of lipoprotein(a) compared with established risk factors in premature coronary artery disease – Differences between men and women. *Atherosclerosis* 1999; 144: 221–228
8. Shai I et al. Lipoprotein(a) and coronary heart disease among women: beyond a cholesterol carrier? *European Heart Journal* 2005; 26: 1633–1639
9. Kamstrup PR et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. *Circulation* 2008; 117(2): 176–184
10. Seed M et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. *NEJM* 1990; 322: 1494–1499

11. Cannon CP et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. *EuropHeartJ* published 2015; 36(19): 1186–1194
12. Sabatine MS et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017; 376(18):1713–722
13. Schwartz GG et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med* 2018; 379(22):2097–2107
14. Klingel R. Lipidapherese bei isolierter Lipoprotein(a)-Erhöhung mit progredienter Gefäßkrankung. *Herzmedizin* 2009; 26(39): 136–139
15. Leebmann J et al. Lipoprotein Apheresis in Patients with Maximally Tolerated Lipid Lowering Therapy, Lp(a)-Hyperlipoproteinemia and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study. *Circulation* 2013; 128(24); 2567–2576

## SPORT IM KARDIOVASKULÄREN RISIKOMANAGEMENT

- **Teil I: Trainingsspezifische Aspekte zur günstigen Beeinflussung kardiovaskulärer Risikofaktoren (S. 34–40)**

*R. G. Ketelhut, K. Ketelhut*

### Literatur

1. MacInnis MJ & Gibala MJ. Physiological adaptations to interval training and the role of exercise intensity. *J Physiol* 2017; 595(9): 2915–2930
2. Karvonen M et al. The effects of training heart rate: a longitudinal study. *Annales Med Experiment Biol Fenniae* 1957; 35: 307–315
3. Godin G et al. Differences in perceived barriers to exercise between high and low intenders: observations among different populations. *Am J Health Prom* 1994; 8: 279–285
4. Kimm SY et al. Self-perceived barriers to activity participation among sedentary adolescent girls. *Med Sci Sports Exerc* 2006; 38(3): 534–540
5. Trost SG et al. Correlates of adults' participation in physical activity: review and update. *Med Sci Sports Exerc* 2002; 34(12): 1996–2001
6. Ketelhut S. Hochintensives Training – auch für Hypertoniker eine Option? *Druckpunkt* 2016; 23(4): 24–27
7. Ketelhut S. HIIT – kurz und intensiv, „alternatives“ Training auch für das Herz. *Praktische Kardiologie – Journal by Fax*. 2015; 24
8. Valstad SA et al. Comparison of Long and Short High-Intensity Interval Exercise Bouts on Running Performance, Physiological and Perceptual Responses. *Sports Med Int Open* 2018; 02(01): e20–e27. DOI: 10.1055/s-0043-124429
9. Campbell WW et al. (For the 2018 Physical Activity Guidelines Advisory Committee). High-Intensity Interval Training for Cardiometabolic Disease Prevention. *Med Sci Sports Exerc* 2019; 51(6): 1220–1226
10. Fulton JE et al. Active video game participation in U.S. youth: Findings from the National Youth Physical Activity and Nutrition Survey, 2010. *Circulation* 2012; 125: AP260

11. Baranowski T et al. Impact of an active video game on healthy children's physical activity. *Pediatrics* 2012; 129(3): e636–e642
12. Daley AJ. Can exergaming contribute to improving physical activity levels and health outcomes in children? *Pediatrics* 2009; 124(2): 763–771
13. Biddiss E & Irwin J. Active video games to promote physical activity in children and youth: a systematic review. *Arch Pediatr Adolesc Med* 2011; 164(7): 664–672
14. Benzing V & Schmidt M. Exergaming for children and adolescents: strengths, weaknesses, opportunities and threats. *Journal of clinical medicine* 2018; 7(11): 422
15. Bailey BW & McInnis K. Energy cost of exergaming: a comparison of the energy cost of 6 forms of exergaming. *Archives of pediatrics & adolescent medicine* 2011; 165(7): 597–602
16. Graves LE et al. The effect of active video gaming on children's physical activity, behavior preferences and body composition. *Pediatr Exerc Sci* 2010; 22(4): 535–46
17. Ramos JS et al. The impact of high-intensity interval training versus moderate-intensity continuous training on vascular function: a systematic review and meta-analysis. *Sports Med.* 2015; 45: 679–92
18. Schjerve IE et al. Both aerobic endurance and strength training programs improve cardiovascular health in obese adults. *Clin Sci* 2008; 115: 283–93
19. Siasos G et al. Acute effects of different types of aerobic exercise on endothelial function and arterial stiffness. *Eur J Prev Cardiol* 2016; 23: 1565–1572
20. Libby P. Inflammation in atherosclerosis. *Arterioscler Thromb Vasc Biol* 2012; 32: 2045–51
21. Libby P et al.: Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week. *J Am Coll Cardiol* 2018; 72: 2071–81
22. Geovanini GR & Libby P. Atherosclerosis and inflammation: overview and updates. *Clin Sci* 2018; 132: 1243–52
23. Vicencio F et al. Effects of physical exercise on oxidative stress biomarkers in hypertensive animals and non-diabetic subjects with prehypertension/hypertension: a review. *Sport Sci Health* 2019; 15(3): 481–495
24. Gehling UM et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. *Blood* 2000; 95: 3106–3122
25. Gunsilius E et al. Contribution of endothelial cells of hematopoietic origin to blood vessel formation. *Cir Res* 2001; 88: E1. <https://doi.org/10.1161/01.RES.88.1.e1>
26. Ribeiro F et al. Effects of exercise training on endothelial progenitor cells in cardiovascular disease: a systematic review. *Am J Phys Med Rehab* 2013; 92(11): 1020–30
27. Guhanarayan G et al. Circulating angiogenic cell population responses to 10 days of reduced physical activity. *J Appl Physiol* 2014; 117: 500–506
28. Ren JM et al. Exercise induces rapid increases in GLUT4 expression, glucose transport capacity, and insulin-stimulated glycogen storage in muscle. *J Biol Chem* 1994; 69: 14396–14401
29. Simoneau JA et al. Skeletal muscle glycolytic and oxidative enzyme capacities are determinants of insulin sensitivity and muscle composition in obese women. *FASEB J* 1995; 9: 273–278

30. Nikkila EA et al. Lipoprotein lipase activity in adipose tissue and skeletal muscle of runners; relation to serum lipoproteins. *Metabolism* 1978; 27: 1661–1671
31. Nikkila EA et al. Relation of plasma high-density lipoprotein cholesterol to lipoprotein-lipase activity in adipose tissue and skeletal muscle of man. *Atherosclerosis* 1978; 29: 497–501
32. Di Loreto C et al. Make Your Diabetic Patients Walk - Long-term impact of different amounts of physical activity on type 2 diabetes. *Diab Care* 2005; 28: 1295–1302
33. Ketelhut RG et al: Fitness in the fit: does physical conditioning affect cardiovascular risk factors in middle-aged marathon runners? *Eur Heart J* 1996; 17: 199–203
34. Hagberg JM et al. Effect of exercise training in 60- to 69-year-old persons with essential hypertension. *Am J Cardiol* 1989; 64(5): 348–353
35. Neilan TG et al. Myocardial injury and ventricular dysfunction related to training levels among nonelite participants in the Boston Marathon. *Circulation* 2006; 114: 2325–2333
36. Vlachopoulos C et al. Arterial stiffness and wave reflection in marathon runners. *Am J Hypertens* 2010; 23: 974–989
37. Grimsmo J et al. High prevalence of atrial fibrillation in long-term endurance cross-country skiers: echocardiographic findings and possible predictors – a 28–30 years follow-up study. *Eur J Cardiovasc Prev Rehab* 2010; 17 (1): 100 DOI:10.1097/HJR.0b013e32833226be